List view / Grid view
Scientists have discovered a dual-drug therapy that dramatically increases leukaemia cell death, offering new hope for patients with acute myeloid leukaemia (AML). By combining SRC and MCL-1 inhibitors, this approach opens the door to more effective treatments.
KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.
Liver-specific knockdown of TRPC3 enhanced alcohol's inhibitory effect on AMPK through a mechanism of Ca2+-dependent CaMKK2 activation.
Using a newly developed algorithm and a validation study, US researchers find that cancer hijacks a class of enzyme mutations to fuel tumorigenesis.
A new study from the University of Pittsburgh and Carnegie Mellon University may solve the puzzle of how cells control their volume.
Scientists have made a breakthrough in how malaria parasites divide and transmit the disease, a major step forward in preventing one of the biggest killer infections in the world.
The length of time that drug molecules attach to their target protein varies greatly and impacts the protein’s behaviour and drug efficacy. In a new study, scientists in Finland have identified some causal factors for this variance, with the hope it will bring clarity for drug developers.
28 May 2021 | By Eurofins DiscoverX* and Tecan
In this on-demand webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery
In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.
Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.
Modulating the TCR signaling pathway using biologics, small molecules or genetic engineering is highly relevant to many therapeutic areas including cancer immunotherapy, adoptive cell therapy, vaccine development and autoimmune disease.
Using cyro-electron microscopy, researchers have imaged the binding site between a molecule and the tumour suppressor protein PP2A, enabling optimisation of the drug compound.
Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.
